Revenio Group Corporation: Revenio Group Corporation's Board of Directors established a Nomination and Remuneration Committee
Revenio Group Corporation, Stock Exchange Release, October 21, 2020 at 19.45
Revenio Group Corporation’s Board of Directors established a Nomination and Remuneration Committee
Revenio Group Corporation's Board of Directors has made a decision to establish a Nomination and Remuneration Committee effective 21st of October 2020.
In accordance with the charter of the Nomination and Remuneration Committee, the Board elected the following members from among its members for the Committee: Ann-Christine Sundell (Chair), Arne Boye Nielsen and Bill Östman.
Revenio Group Corporation
Board of Directors
For further information, please contact:
Jouni Toijala, CEO, tel. +358 50 484 0085
Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
The Revenio Group in brief
Revenio is a health tech group operating on the international market and a global leader in ophthalmological devices. Revenio Group's ophthalmic diagnostic solutions include intraocular pressure measurement devices under the iCare brand, retinal imaging devices and perimeters. The main tools for the detection and diagnosis of glaucoma and its monitoring during treatment are intraocular pressure measurement (tonometry), retinal imaging, and visual field tests (perimetry).
The Revenio Group comprises Revenio Group Oyj, Icare Finland Oy, Icare USA Inc., Revenio Italy S. R. L, CenterVue SpA, Revenio Research Oy, Done Medical Oy and Oscare Medical Oy.
In 2019, the Group's net sales totaled EUR 49.5 million, with its operating profit standing at 25.5%. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.